Short Interest in Equillium, Inc. (NASDAQ:EQ) Decreases By 45.9%

Equillium, Inc. (NASDAQ:EQ) saw a significant drop in short interest in February. As of February 28th, there was short interest totalling 363,900 shares, a drop of 45.9% from the February 13th total of 672,300 shares. Based on an average daily volume of 770,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 2.1% of the company’s stock are sold short.

Equillium Price Performance

NASDAQ EQ traded down $0.01 during trading on Friday, hitting $0.77. The company’s stock had a trading volume of 23,019 shares, compared to its average volume of 363,169. The company has a market cap of $27.14 million, a PE ratio of -5.47 and a beta of 1.87. The business’s 50 day simple moving average is $0.76 and its 200-day simple moving average is $0.82. Equillium has a fifty-two week low of $0.49 and a fifty-two week high of $2.99.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Equillium stock. DCF Advisers LLC boosted its stake in shares of Equillium, Inc. (NASDAQ:EQ) by 91.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 62,947 shares of the company’s stock after acquiring an additional 29,985 shares during the quarter. DCF Advisers LLC owned 0.18% of Equillium worth $47,000 at the end of the most recent reporting period. Institutional investors own 27.05% of the company’s stock.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.